Jules L.L.M. Coenen

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

Sushil K. Badrising, Vincent van der Noort, Inge M. van Oort et al. · Cancer · 2013 · 135 citations

Medicine, Oncology, Pharmacology +16

Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry

Hans M. Westgeest, Carin A. Uyl‐de Groot, R. Jeroen A. van Moorselaar et al. · European Urology Focus · 2016 · 56 citations · Full text

Medicine, Oncology, Urology +14

Dose Intensity of Standard Adjuvant CMF with Granulocyte Colony-Stimulating Factor for Premenopausal Patients with Node-Positive Breast Cancer

Hiltje de Graaf, Pax H.B. Willemse, Barbara Bong et al. · Oncology · 2009 · 45 citations

Medicine, Oncology, Pharmacology +14

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate‐resistant prostate cancer previously treated with docetaxel

Michel D. Wissing, Jules L.L.M. Coenen, Pieter van den Berg et al. · International Journal of Cancer · 2014 · 43 citations · Full text

Medicine, Oncology, Pharmacology +16

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma

Hanneke C. Kluin‐Nelemans, Jules L.L.M. Coenen, James E. Boers et al. · Blood · 2008 · 43 citations · Full text

Life Sciences, Hematology, Oncology +7